{"id":165,"date":"2022-10-04T18:17:59","date_gmt":"2022-10-04T16:17:59","guid":{"rendered":"https:\/\/stage.fzmb.de\/products\/"},"modified":"2026-02-11T16:30:01","modified_gmt":"2026-02-11T15:30:01","slug":"products","status":"publish","type":"page","link":"https:\/\/www.fzmb.de\/en\/products\/","title":{"rendered":"Products"},"content":{"rendered":"
\n
\n

ELISA and rapid tests<\/h2>\n <\/header>\n
\n
\n
ELISA for the quantitative measurement of vWF-PP<\/div>
Rapid test for the determination of botulinum toxin A and B<\/div>
Rapid test + ELISA for the determination of equine MMP-9<\/div>
ELISA for the quantitative determination of feline trypsion gene (fTLI)<\/div>
Rapid test for virulence factor LukF-P83 in S. aureus<\/div> <\/div>\n
\n \"Foto_Ausschnitt_vwF:PP_ELISA_Kit\" <\/div>\n <\/div>\n
\n

vWF-PP ELISA<\/strong><\/h4>\n

ELISA for quant. measurement of the von Willebrand factor propeptide (vWF-PP) <\/strong><\/p>\n

\"Photo<\/p>\n

 <\/p>\n

 <\/p>\n

Von Willebrand factor (VWF) has several important functions in primary hemostasis. The multimeric protein is found in plasma, platelets and endothelial cells. VWF is also a carrier protein and stabilizer for clotting factor VIII (FVIII) in plasma.<\/p>\n

During the biosynthesis of VWF multimers, a 100 kDa glycoprotein propeptide (VWF:PP) is proteolytically cleaved and released into plasma. In certain types of VWF disorders, including inherited or acquired forms, mutations, and some other diseases, abnormal levels of both VWF:PP and VWF:AG (VWF antigen) or VWF activity may be detected, as reflected by the ratio of VWF:PP and VWF:AG.<\/p>\n

People with VWF disease show an increased tendency to bleed, e.g. epistaxis, bleeding gums, hematomas or excessive bleeding after dental or other surgical procedures. In extreme cases of absolute deficiency (VWF disease type 3), life-threatening bleeding can occur. In blood, VWF and VWF:PP have very different half-lives (12 versus 2 hours). Measurement of VWF:PP, in addition to VWF:AG, is an important tool for characterizing the nature of VWF deficiency, particularly in individuals with a shortened plasma half-life of VWF.<\/p>\n

The wells of the microplate strips included in this kit are coated with a monoclonal antibody directed against VWF:PP. The sample is pipetted into a well followed by a second monoclonal antibody against VWF:PP conjugated to an enzyme. VWF:PP binds to the antibody bound to the solid phase and is immobilized.<\/p>\n

The second antibody with the conjugated enzyme also binds to the immobilized VWF:PP. After incubation and washing steps, all unbound material is removed, and the added substrate is cleaved by the bound enzyme of the conjugate, releasing a dye in proportion to the bound VWF:PP. The reaction is stopped after a certain time and the absorption is measured. This shows the concentration of VWF:PP.<\/p>\n

The assay is calibrated by parallel measurement of the supplied calibrator and its dilutions against a calibration curve. Quality control is possible by simultaneous analysis of the control plasma included in the kit.<\/p>\n

Product number: <\/strong>13.02.095.0096 (processing by pipetting robot), 13.02.095.1096 (manual processing)<\/p>\n

Product Name: <\/strong>INTER-ARRAY VFW:PP ELISA Kit – Enzyme linked immunosorbent assay (ELISA) for the quantitative determination of von Willebrand factor propeptide (VWF:PP) in human blood plasma. For research purposes only.<\/p>\n

Product content: <\/strong>The ready-to-use kit is available in two versions from our distributors: for manual processing in the laboratory or for use with automated pipetting systems. In addition to the individually packaged antibody-coated microplate strips, all reagents required for processing as well as lyophilized calibrator and control plasma are included.<\/p>\n

 <\/p>\n

Literature\/ Data sheets<\/strong><\/p>\n

Flyer VWF-PP ELISA<\/a><\/p>\n

 <\/p>\n

Inquiries and orders<\/strong><\/p>\n

inter-array@fzmb.de<\/a><\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n<\/div>

Bot. Tox. A Abicap SL 24 Kit \/ Bot. Tox. B Abicap SL 24 Kit<\/h4>\n

Immunoassay for the detection of botulinum toxin A or botulinum toxin B<\/strong><\/p>\n

The Abicap columns used contain three 3-dimensional filters: two spacer filters (1.6 x 5 mm) coated with BSA and, in between, a measurement filter (2.5 x 5 mm) coated with capture antibodies directed against botulinum toxin A1\/2 and botulinum toxin B, respectively.<\/p>\n

In the first step, the pre-incubated sample is applied to the Abicap column and captured by the specific antibody on the filter surface. The sandwich complexes are detected by addition of streptavidin-poly-horseradish peroxidase and tetramethyl-benzidine substrate solution. The enzymatic reaction results in a blue precipitate on the filter surface with an optical density proportional to the toxin concentration.<\/p>\n

Measuring range in sample dilution buffer: 5-100 U\/ml or 5-500 U\/ml.<\/p>\n

Product number: <\/strong>13.02.071.0240 (Bot. Tox. A<\/strong> Abicap SL 24 Kit) and 13.02.072.0240 (Bot. Tox. B<\/strong> Abicap SL 24 Kit)<\/p>\n

Product name: <\/strong>Bot. Tox. A Abicap SL 24 Kit and Bot. Tox. B Abicap SL 24 Kit – Test kits for the determination of botulinus toxin A or botulinus toxin B. For research purposes only.<\/p>\n

Product content: <\/strong>In addition to the individually packaged Abicap columns loaded with antibody-coated microfilters, all reagents required for processing are included.<\/p>\n

 <\/p>\n

Inquiries and orders<\/strong><\/p>\n

inter-array@fzmb.de<\/a><\/p>\n

 <\/p>\n<\/div>

MMP-9 rapid test<\/strong><\/h4>\n

Lateral Flow Assay <\/strong>for the detection of MMP-9 (matrix metalloprotease 9) in body fluids of horses<\/strong><\/p>\n

 <\/p>\n

 <\/p>\n

Usage<\/strong><\/p>\n

The MMP-9 rapid test is a visual POC test for the qualitative detection of metallomatrix protease 9 in the body fluid of horses. This kit is intended as an aid in the assessment of protease activity and is intended for in vitro diagnostic use by professionals only.<\/p>\n

 <\/p>\n

 <\/p>\n

Background information<\/strong><\/p>\n

Matrix metalloproteinases (MMPs) play a key role in degenerative processes, making them a predestined biomarker in equine inflammatory diseases (Clutterbuck et al. 2010). MMP-9 is causally involved in cartilage degradation in joint disease (Clegg and Carter 1999; Clegg et al. 1997) and is therefore used as a marker in lameness. MMP-9 concentrations in plasma and peritoneal fluid are also elevated in horses with colic symptoms and a positive sepsis score (Barton et al. 2021).<\/p>\n

During surgical treatment of recurrent uveitis (ERU) by vitrectomy, MMP-9 rapid analysis can be used for intraoperative monitoring to assess the progress of surgery.<\/p>\n

With the MMP-9 rapid test specific for horses, time-consuming and labor-intensive laboratory methods such as zymography and ELISA can be avoided and a result is available within a few minutes. However, for accurate quantification of MMP-9 content, the equine-specific MMP-9 ELISA should be performed.<\/p>\n

 <\/p>\n

 <\/p>\n

Test principle<\/strong><\/p>\n

The MMP-9 rapid test is a sandwich immunoassay for the detection of matrix metalloprotea 9 in body fluids of horses by visual interpretation of the color development in the test cassette. The membrane was coated with an antibody against equine MMP-9 in the test line region (T). During the assay, the diluted sample reacts with a stained conjugate (anti-equine-MMP-9 antibody gold conjugate) that has been added to the pad inside the test cassette.<\/p>\n

The mixture moves chromatographically across the membrane by capillary action. If MMP-9 is present in the sample, a colored line with a specific antibody-antigen conjugate complex forms in the test line region (T) of the membrane. This complex consists of a stained anti-MMP-9 antibody, MMP-9 from the sample, and the antibody fixed on the membrane in the test line region (T).<\/p>\n

On the other hand, a colored line always appears in the control region (C). For this purpose, another antigen-antibody reaction (with antimouse antibodies) is used. This control line serves as a procedural indicator of the proper functioning of the test. It indicates that the test procedure has been performed correctly and that the sample has flowed properly across the membrane.<\/p>\n

A pronounced color development in the test line region (T) indicates a positive result (MMP-9 present in the sample). The absence of a color line in the test line region (T) indicates a negative result (no MMP-9 present in the sample).<\/p>\n

 <\/p>\n

 <\/p>\n

MMP-9 ELISA<\/strong><\/h4>\n

ELISA for the detection of MMP9 <\/strong>(equine matrix metalloprotease 9)<\/strong><\/p>\n

in body fluids of horses<\/strong><\/p>\n

 <\/p>\n

Product name:<\/strong> eqMMP-9 FAST ELISA Kit<\/p>\n

The MMP-9 ELISA is an immunological enzymatic detection method for the detection of equine matrix metalloproteinase 9 (eqMMP-9, gelatinase B, 92 kDa gelatinase, 92 kDa type IV collagenase, MMP-9) in equine body fluids.<\/p>\n

eqMMP can be detected in various body fluids of horses including synovial fluid, vitreous fluid and bronchoalveolar lavage<\/span><\/span> fluid <\/span>(BALF).<\/p>\n

The monoclonal antibodies used in the kit<\/a> were generated against native equine MMP-9.<\/p>\n

The ELISA is suitable for use by qualified personnel in the veterinary diagnostic field.<\/p>\n

 <\/p>\n

Inquiries and orders<\/strong><\/p>\n

irichter@fzmb.de<\/a><\/p>\n

 <\/p>\n

 <\/p>\n

About MMP-9<\/strong><\/p>\n

Matrix metalloprotease 9 (MMP-9) is also known as 92 kDa type IV collagenase, 92 kDa gelatinase or gelatinase B.<\/p>\n

MMP-9 is therefore a predestined biomarker for inflammatory diseases in horses. Matrix metalloprotease 9 is involved in a large number of physiological processes. <\/p>\n

MMP-9 is suitable as a biomarker e.g.<\/p>\n